{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:57:21Z","timestamp":1787237841996,"version":"build-2736575974"},"reference-count":37,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Cirrhosis is characterized by complications, including hepatic encephalopathy (HE), hepatorenal syndrome (HRS), and acute variceal bleeding, Glucagon-like peptide-1 (GLP-1) analogs, have shown potential benefits in reducing liver inflammation and lowering cirrhosis-related complications. This study aims to provide insights into the effect of GLP-1 therapy on mortality and clinical outcomes in patients with cirrhosis.  Methods: We conducted a retrospective analysis using TriNetX research network. The cohort comprised patients \u226518 years old with a diagnosis of cirrhosis. Patients who were started on GLP-1 analogs after the diagnosis of cirrhosis were identified. Primary outcomes included all-cause mortality, HE, HRS, and portal hypertensive bleeding. Variables such as age, sex, race, comorbidities (e.g., diabetes, obesity, chronic kidney disease, hypertension), and lifestyle factors underwent 1:1 propensity matching to reduce confounding. Cox proportional hazards regression analysis was utilized to analyze the matched cohorts, and hazard ratios (HR) with 95% confidence intervals.  Results: GLP-1 analog use was significantly associated with a reduced risk of several cirrhosis-related complications. Patients treated with GLP-1 analogs exhibited a significantly lower risk of all-cause mortality (HR 0.374, 95%CI 0.359-0.392), HE (HR 0.900, 95%CI 0.843-0.959), and HRS (HR 0.554, 95%CI 0.496-0.619). Additionally, there was reduced rates of portal hypertensive bleeding among GLP-1 users (HR 0.487, 95%CI 0.444-0.533).  Conclusion: This study demonstrates that GLP-1 analog use is associated with a significantly lower risk of all-cause mortality and cirrhosis-related complications. Furthermore, the reduced rate of portal hypertensive bleeding might correlate with subsequent decrease in hospitalizations.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612025-130","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:43:48Z","timestamp":1780656228000},"source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 AND CIRRHOSIS: EFFECTS ON MORTALITY AND LIVER-RELATED COMPLICATIONS"],"prefix":"10.1590","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5674-3424","authenticated-orcid":false,"given":"Chidera N","family":"ONWUZO","sequence":"first","affiliation":[{"name":"SUNY Upstate Medical University,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3290-9931","authenticated-orcid":false,"given":"Odusanya Kikunlore","family":"ELIJAH","sequence":"additional","affiliation":[{"name":"Olabisi Onabanjo University Teaching Hospital,  Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8273-5252","authenticated-orcid":false,"given":"FNU","family":"ALVINA","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-3294","authenticated-orcid":false,"given":"Rashid Abdel","family":"RAZEQ","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Fairview Hospital,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8163-9889","authenticated-orcid":false,"given":"KOJO-FRIMPONG B.","family":"AWUAH","sequence":"additional","affiliation":[{"name":"Allegheny General Health,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5060-3131","authenticated-orcid":false,"given":"Somtochukwu","family":"ONWUZO","sequence":"additional","affiliation":[{"name":"Allegheny General Health,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s P","year":"2021","journal-title":"The Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani SK","year":"2019","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal AJ","year":"2019","journal-title":"Nature reviews Gastroenterology & hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.cgh.2021.09.023","article-title":"Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis","volume":"20","author":"Morris SM","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management","volume":"15","author":"Garcia-Compean D","year":"2009","journal-title":"World J Gastroenterol"},{"key":"ref6","article-title":"Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes","volume":"22","author":"Yen FS","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jgh.16752","article-title":"Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis","volume":"40","author":"Passos PRC","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis [LEAN]: a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","journal-title":"The Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong MJ","year":"2016","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes","volume":"20","author":"Simon TG","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou SG","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management","volume":"15","author":"Garcia-Compean D","year":"2009","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan N","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"101272","DOI":"10.1016\/j.diabet.2021.101272","article-title":"Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement","volume":"47","author":"Boursier J","year":"2021","journal-title":"Diabetes Metab"},{"key":"ref15","first-page":"555","article-title":"Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus","volume":"36","author":"Huynh DJ","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz EJ","year":"2024","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins [GLP-1 receptor agonists and dual\/triple agonists] and the liver","volume":"79","author":"Newsome PN","year":"2023","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coph.2016.08.005","article-title":"GLP-1 as a target for therapeutic intervention","volume":"31","author":"Rajeev SP","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives","volume":"24","author":"Nevola R","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann JFE","year":"2017","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","journal-title":"Molecular metabolism"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","journal-title":"The Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid MI","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","article-title":"Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes","volume":"73","author":"Wester A","year":"2024","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.gastro.2007.04.007","article-title":"Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis","volume":"133","author":"Marzioni M","year":"2007","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-02866-y","article-title":"Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies","volume":"7","author":"De Mesquita FC","year":"2017","journal-title":"Scientific reports"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"Engelmann C","year":"2021","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher G","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","article-title":"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"18","author":"Fang L","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"609110","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong C","year":"2021","journal-title":"Frontiers in endocrinology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cld.650","article-title":"Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside","volume":"10","author":"Armstrong MJ","year":"2017","journal-title":"Clin Liver Dis"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 [GLP-1] analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong V","year":"2023","journal-title":"JCI Insight"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"599646","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats","volume":"14","author":"Marty VN","year":"2020","journal-title":"Frontiers in neuroscience"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000561","article-title":"Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists","volume":"8","author":"Jensen EL","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang W","year":"2024","journal-title":"Nature communications"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/L20-0041","article-title":"The effect of liraglutide on \u03b2-blockade for preventing variceal bleeding: a case series","volume":"173","author":"Vukotic R","year":"2020","journal-title":"Annals of internal medicine"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["GLP-1 e cirrose: efeitos na mortalidade e nas complica\u00e7\u00f5es hep\u00e1ticas relacionadas"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032026000101403&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:43:54Z","timestamp":1780656234000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032026000101403&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"alternative-id":["S0004-28032026000101403"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612025-130","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e25130"}}